NextCure, Inc. NXTC
NextCure, Inc. (Nasdaq: NXTC) is an oncology drug developer. Its lead program is in Pre-clinical.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SIM0505 (CDH6 ADC; licensed from Simcere Zaiming, ex-China rights) | Platinum-resistant ovarian cancer and other solid tumors | antibody | Phase 1 |
| LNCB74 (B7-H4 ADC; LigaChem) | Breast, ovarian, endometrial and other B7-H4-expressing cancers | antibody | Phase 1 |
Recent results and decisions
- Jun 1, 2026positive SIM0505 showed 55% ORR (11/20) in gynecologic cancers (52.9% in ovarian, 9/17) at 4.8-8.0 mg/kg in evaluable pts with >=12 wks follow-up; Grade>=3 TEAEs 54.2%, data cut 07Apr26 (n=59).
55% ORR in gynecologic cancers
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.